Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Raltegravir pharmacokinetics in neonates following maternal dosing.
Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, Handelsman E, Teppler H, Welebob C, Persaud D, Cababasay MP, Wang J, Mirochnick M; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1097 Study Team. Clarke DF, et al. Among authors: cababasay mp. J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):310-5. doi: 10.1097/QAI.0000000000000316. J Acquir Immune Defic Syndr. 2014. PMID: 25162819 Free PMC article. Clinical Trial.
Pharmacokinetics of oral zidovudine administered during labour: a preliminary study.
Mirochnick M, Rodman JH, Robbins BL, Fridland A, Gandía J, Hitti J, Bardeguez A, Rathore MH, Gonzalez Garcia A, Cababasay M, Samson P, Mofenson L, Bryson YJ, Dorenbaum A. Mirochnick M, et al. HIV Med. 2007 Oct;8(7):451-6. doi: 10.1111/j.1468-1293.2007.00495.x. HIV Med. 2007. PMID: 17760737 Free article.
Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial.
Flynn PM, Taha TE, Cababasay M, Fowler MG, Mofenson LM, Owor M, Fiscus S, Stranix-Chibanda L, Coutsoudis A, Gnanashanmugam D, Chakhtoura N, McCarthy K, Mukuzunga C, Makanani B, Moodley D, Nematadzira T, Kusakara B, Patil S, Vhembo T, Bobat R, Mmbaga BT, Masenya M, Nyati M, Theron G, Mulenga H, Butler K, Shapiro DE; PROMISE Study Team. Flynn PM, et al. J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):383-392. doi: 10.1097/QAI.0000000000001612. J Acquir Immune Defic Syndr. 2018. PMID: 29239901 Free PMC article. Clinical Trial.
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).
Clarke DF, Acosta EP, Cababasay M, Wang J, Chain A, Teppler H, Popson S, Graham B, Smith B, Hazra R, Calabrese K, Bryson Y, Spector SA, Lommerse J, Mirochnick M; IMPAACT P1110 Protocol Team. Clarke DF, et al. J Acquir Immune Defic Syndr. 2020 May 1;84(1):70-77. doi: 10.1097/QAI.0000000000002294. J Acquir Immune Defic Syndr. 2020. PMID: 31913995 Free PMC article. Clinical Trial.
Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
Aizire J, Brooks KM, Mirochnick M, Flynn PM, Butler K, Kiser JJ, Siberry GK, Fenton T, Cababasay M, Fowler MG; PROMISE Study Team. Aizire J, et al. J Acquir Immune Defic Syndr. 2020 Feb 1;83(2):173-180. doi: 10.1097/QAI.0000000000002247. J Acquir Immune Defic Syndr. 2020. PMID: 31929405 Free PMC article. Clinical Trial.
Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097.
Clarke DF, Lommerse J, Acosta EP, Cababasay MP, Wang J, Spector SA, Chain A, Smith E, Teppler H, Hazra R, Calabrese K, Graham B, Popson S, Bryson Y, Mirochnick M; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1097 Study Team. Clarke DF, et al. Among authors: cababasay mp. J Acquir Immune Defic Syndr. 2020 Dec 15;85(5):626-634. doi: 10.1097/QAI.0000000000002492. J Acquir Immune Defic Syndr. 2020. PMID: 32925360 Free PMC article.
Association of Maternal Viral Load and CD4 Count With Perinatal HIV-1 Transmission Risk During Breastfeeding in the PROMISE Postpartum Component.
Flynn PM, Taha TE, Cababasay M, Butler K, Fowler MG, Mofenson LM, Owor M, Fiscus S, Stranix-Chibanda L, Coutsoudis A, Gnanashanmugam D, Chakhtoura N, McCarthy K, Frenkel L, Beck I, Mukuzunga C, Makanani B, Moodley D, Nematadzira T, Kusakara B, Patil S, Vhembo T, Bobat R, Mmbaga BT, Masenya M, Nyati M, Theron G, Mulenga H, Shapiro DE; PROMISE Study Team. Flynn PM, et al. J Acquir Immune Defic Syndr. 2021 Oct 1;88(2):206-213. doi: 10.1097/QAI.0000000000002744. J Acquir Immune Defic Syndr. 2021. PMID: 34108383 Free PMC article. Clinical Trial.
Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study.
Bekker A, Capparelli EV, Violari A, Cotton MF, Cababasay M, Wang J, Mathiba R, Wiesner L, Wiznia A, Samson P, Browning R, Moye J, Nakwa FL, Decloedt E, Rabie H, Mirochnick M, Cressey TR; IMPAACT P1106 team. Bekker A, et al. Lancet HIV. 2022 Jan;9(1):e24-e31. doi: 10.1016/S2352-3018(21)00266-6. Epub 2021 Dec 6. Lancet HIV. 2022. PMID: 34883066 Free PMC article.
Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure.
Béranger A, Bekker A, Solans BP, Cotton MF, Mirochnick M, Violari A, Wang J, Cababasay M, Wiesner L, Browning R, Moye J, Capparelli EV, Savic RM. Béranger A, et al. Clin Infect Dis. 2022 Sep 29;75(6):1037-1045. doi: 10.1093/cid/ciac001. Clin Infect Dis. 2022. PMID: 35134861 Free PMC article.
13 results